卡格列净对2型糖尿病合并慢性肾脏病患者贫血的影响:CREDENCE试验事后分析
CREDENCE试验事后分析纳入4401例2型糖尿病合并慢性肾脏病患者,随机接受卡格列净100mg或安慰剂。
要点
- 卡格列净降低贫血事件、铁剂启动和促红细胞生成素需求风险。
核心结论
- 卡格列净可降低2型糖尿病合并慢性肾脏病患者贫血相关结局风险,包括对促红细胞生成素的需求。
研究设计与样本
- CREDENCE试验事后分析,纳入4401例2型糖尿病合并慢性肾脏病患者,随机分至卡格列净100mg组(n=2202)或安慰剂组(n=2199),来自34个国家690个中心。
- 采用线性混合效应模型评估血红蛋白和血细胞比容变化,主要终点为研究者报告的贫血或贫血治疗的复合终点,采用Kaplan-Meier分析和Cox回归模型,意向性治疗分析。
关键数值与推荐
- 贫血定义为男性血红蛋白<130 g/L或女性<120 g/L;基线时1599例(36%)存在贫血。
- 573例发生贫血事件或启动贫血治疗;358例(8%)报告贫血事件,343例(8%)启动铁剂,141例(3%)启动促红细胞生成素,114例(2%)接受输血。
临床怎么用
- 对于2型糖尿病合并慢性肾脏病患者,卡格列净治疗可能有助于改善血红蛋白和血细胞比容,并减少贫血相关治疗需求。
局限性
- 为事后分析,结果需谨慎解释。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sodium-glucose co-transporter 2 inhibitors might enhance erythropoiesis and increase red blood cell mass. We assessed the long-term effects of canagliflozin on anaemia-related outcomes. METHODS: In a post-hoc analysis of the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial, we included patients with type 2 diabetes and chronic kidney disease who were randomly assigned to treatment with canagliflozin or placebo at 690 sites in 34 countries. We assessed the effects of canagliflozin versus matched placebo on haemoglobin and haematocrit using linear mixed-effects models. The primary outcome of this post-hoc analysis was a composite outcome of investigator-reported anaemia or treatment for anaemia, which was assessed using Kaplan-Meier analysis and Cox regression models. All analyses were done by intention to treat. FINDINGS: Between March 24, 2014, and May 5, 2017, 4401 participants were randomly assigned to receive canagliflozin (100 mg; n=2202) or placebo (n=2199). At baseline, mean haemoglobin concentration was 132·0 g/L (SD 17·7), 1599 (36%) of 4401 participants had anaemia (defined as haemoglobin <130 g/L in men or <120 g/L in women), and 33 (<1%) of 4401 participants used erythropoiesis-stimulating agents. During a median follow-up period of 2·6 years (IQR 2·1-3·1), mean haemoglobin concentration was 7·1 g/L (95% CI 6·4-7·8) higher and haematocrit was 2·4% (2·2-2·6) higher in the canagliflozin group than the placebo group. Overall, 573 of 4401 participants had either an investigator-reported anaemia event or initiation of treatment for anaemia: 358 (8%) of 4401 participants reported anaemia events, 343 (8%) initiated iron preparations, 141 (3%) initiated erythropoiesis-stimulating agents, and 114 (2%) received blood transfusion. The risk of the composite outcome of anaemia events or initiation of treatment for anaemia was lower in the canagliflozin group than the placebo group (hazard ratio 0·65, 95% CI 0·55-0·77; p<0·0001). Compared with the placebo group, participants in the canagliflozin group also had lower risks of anaemia events alone (0·58, 0·47-0·72; p<0·0001), initiation of iron preparations (0·64, 0·52-0·80; p<0·0001), and need for erythropoiesis-stimulating agents (0·65, 0·46-0·91; p=0·012). INTERPRETATION: These data suggest that canagliflozin reduces the risk of anaemia-associated outcomes, including the need for erythropoiesis-stimulating agents, among patients with type 2 diabetes and chronic kidney disease. FUNDING: Janssen Research and Development.
引用
- Oshima M, Neuen BL, Jardine MJ, et al. Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial. Lancet Diabetes Endocrinol. 2020. PMID: 33065060. doi:10.1016/S2213-8587(20)30300-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。